… (FOG), which are brief but severe episodes of inability to walk. Walking is controlled by a brain region called the … Changes in brain activity here are known to relate to how the legs move as measured with electrodes on the brain … activity during normal walking and FOG can be recorded and compared. Next, we will see the effects on leg movements and …

… Glucocerebrosidase (GCase) is an enzyme that is linked to Parkinson’s disease (PD) and is a high value target for … GCase activity specifically in lysosomes, the subcellular compartment in which the enzyme normally functions. … be more accurate than conventional assays and will improve how we assess and follow up individuals with or at risk of …

… (PD) would be significantly improved if we had a way to directly monitor disease development and progression in … in blood-borne EVs that originated in the brain. We will compare these RNAs with RNAs from the brains of the same individuals to assess how well EVs reflect RNA changes in brain. Hypothesis:  We …

… Update as of December 9, 2024:  In a long-sought victory for the Parkinson’s community, the U.S. Environmental Protection Agency (EPA) … trichloroethylene (TCE).  Learn more about the TCE ban and how you can help us make a final push for the EPA to ban …

… This week, competing reports on cholesterol lowering drugs called … of cognitive side effects.  This information will be added to the labels of brand names such as Lipitor, Zocor, and Crestor. How can statins both lower risk for a neurological disease …

… There is a pressing need for new treatments to address cognitive impairment in Parkinson’s disease, yet there is no consensus on how to best evaluate their effectiveness. Treatment trials … Future projects would involve using the UPSA as an outcome measure for a treatment trial evaluating functional …